Clinical Trials

Vaxil BioTherapeutics is evaluating ImMucin, a new drug for cancer, which works to activate specialized white blood cells of the patient’s immune system against cancer cells.
This page contains information on ImMucin clinical trials around the world.

All reasonable precautions have been taken to ensure the accuracy of the information available through the site. Vaxil may amend the information at any time without notice.

• DRUG: MUC1 Peptide-based cancer vaccine, ImMucin
• SPONSOR: Vaxil BioTherapeutics Ltd.
• STUDY CODE: VAXIL-010
• STATUS: Open for candidates
  
• OBJECTIVE:
  > Evaluate the tolerability and safety of the ImMucin peptide vaccine alone or in combination with GM-CSF in patients with metastatic breast cancer undergoing hormone treatment.
  > Evaluate the development of immune and clinical response following ImMucin's treatment 
• PARTICIPATING CENTERS: Hadassah Medical Centers, Israel
• INFORMATION:

DISCLAIMER: Information contained anywhere within this website is not intended to replace the advice of a healthcare professional. In no circumstances must it be considered as a treatment.

Back to top